CN114292327A - 一种广谱新型冠状病毒的人源抗体及其应用 - Google Patents
一种广谱新型冠状病毒的人源抗体及其应用 Download PDFInfo
- Publication number
- CN114292327A CN114292327A CN202210228772.5A CN202210228772A CN114292327A CN 114292327 A CN114292327 A CN 114292327A CN 202210228772 A CN202210228772 A CN 202210228772A CN 114292327 A CN114292327 A CN 114292327A
- Authority
- CN
- China
- Prior art keywords
- seq
- antibody
- human antibody
- antigen
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 17
- 239000000427 antigen Substances 0.000 claims abstract description 29
- 102000036639 antigens Human genes 0.000 claims abstract description 29
- 108091007433 antigens Proteins 0.000 claims abstract description 29
- 230000027455 binding Effects 0.000 claims description 32
- 241001678559 COVID-19 virus Species 0.000 claims description 28
- 239000012634 fragment Substances 0.000 claims description 17
- 239000002773 nucleotide Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 230000035772 mutation Effects 0.000 claims description 11
- 239000013604 expression vector Substances 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 239000002671 adjuvant Substances 0.000 claims 1
- 241001112090 Pseudovirus Species 0.000 abstract description 20
- 238000006386 neutralization reaction Methods 0.000 abstract description 7
- 230000003472 neutralizing effect Effects 0.000 abstract description 7
- 238000012216 screening Methods 0.000 abstract description 7
- 238000000338 in vitro Methods 0.000 abstract description 6
- 230000005540 biological transmission Effects 0.000 abstract description 2
- 230000000750 progressive effect Effects 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 description 25
- 150000001413 amino acids Chemical group 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 19
- 239000013612 plasmid Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 229960000723 ampicillin Drugs 0.000 description 10
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 10
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 239000002808 molecular sieve Substances 0.000 description 9
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000012855 volatile organic compound Substances 0.000 description 5
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 4
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 101000674040 Homo sapiens Serine-tRNA ligase, mitochondrial Proteins 0.000 description 4
- 102100040597 Serine-tRNA ligase, mitochondrial Human genes 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 210000003501 vero cell Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 208000025721 COVID-19 Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 238000012917 library technology Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002019 anti-mutation Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 101100364969 Dictyostelium discoideum scai gene Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101100364971 Mus musculus Scai gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101150062156 RBD2 gene Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001808 coupling effect Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000012482 interaction analysis Methods 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- ZRHANBBTXQZFSP-UHFFFAOYSA-M potassium;4-amino-3,5,6-trichloropyridine-2-carboxylate Chemical group [K+].NC1=C(Cl)C(Cl)=NC(C([O-])=O)=C1Cl ZRHANBBTXQZFSP-UHFFFAOYSA-M 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (18)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210228772.5A CN114292327B (zh) | 2022-03-10 | 2022-03-10 | 一种广谱新型冠状病毒的人源抗体及其应用 |
PCT/CN2022/085186 WO2023168776A1 (zh) | 2022-03-10 | 2022-04-02 | 一种广谱新型冠状病毒的人源抗体及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210228772.5A CN114292327B (zh) | 2022-03-10 | 2022-03-10 | 一种广谱新型冠状病毒的人源抗体及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114292327A true CN114292327A (zh) | 2022-04-08 |
CN114292327B CN114292327B (zh) | 2022-07-12 |
Family
ID=80978634
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210228772.5A Active CN114292327B (zh) | 2022-03-10 | 2022-03-10 | 一种广谱新型冠状病毒的人源抗体及其应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114292327B (zh) |
WO (1) | WO2023168776A1 (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114907484A (zh) * | 2022-04-20 | 2022-08-16 | 中国科学院微生物研究所 | 一种强效抗新冠突变株包括奥密克戎四种亚型的双特异人源抗体 |
CN115453113A (zh) * | 2022-04-13 | 2022-12-09 | 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) | 一种广谱性通用型新型冠状病毒双抗原夹心elisa抗体检测试剂盒及其应用 |
CN116284363A (zh) * | 2023-05-15 | 2023-06-23 | 北京百普赛斯生物科技股份有限公司 | 新型冠状病毒OmicronBA.2/4/5突变株特异性抗体及其应用 |
WO2024022438A1 (zh) * | 2022-07-29 | 2024-02-01 | 盛禾(中国)生物制药有限公司 | 一种抗rbd抗体及其用途 |
WO2024102674A1 (en) * | 2022-11-13 | 2024-05-16 | Generate Biomedicines, Inc. | Antigen binding molecules targeting sars-cov-2 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022022445A1 (zh) * | 2020-07-28 | 2022-02-03 | 上海市公共卫生临床中心 | 一种特异性结合冠状病毒的抗体或其抗原结合片段 |
CN114031685A (zh) * | 2022-01-10 | 2022-02-11 | 中国人民解放军军事科学院军事医学研究院 | 一种全人源抗新冠病毒广谱中和抗体zw2g10及应用 |
CN114044821A (zh) * | 2022-01-10 | 2022-02-15 | 中国人民解放军军事科学院军事医学研究院 | 一种抗新冠病毒全人源广谱中和抗体zwc12及应用 |
-
2022
- 2022-03-10 CN CN202210228772.5A patent/CN114292327B/zh active Active
- 2022-04-02 WO PCT/CN2022/085186 patent/WO2023168776A1/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022022445A1 (zh) * | 2020-07-28 | 2022-02-03 | 上海市公共卫生临床中心 | 一种特异性结合冠状病毒的抗体或其抗原结合片段 |
CN114031685A (zh) * | 2022-01-10 | 2022-02-11 | 中国人民解放军军事科学院军事医学研究院 | 一种全人源抗新冠病毒广谱中和抗体zw2g10及应用 |
CN114044821A (zh) * | 2022-01-10 | 2022-02-15 | 中国人民解放军军事科学院军事医学研究院 | 一种抗新冠病毒全人源广谱中和抗体zwc12及应用 |
Non-Patent Citations (1)
Title |
---|
BIN JU ET AL: "Immune escape by SARS-CoV-2 Omicron variant and structural basis of its effective neutralization by a broad neutralizing human antibody VacW-209", 《CELL RESEARCH》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115453113A (zh) * | 2022-04-13 | 2022-12-09 | 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) | 一种广谱性通用型新型冠状病毒双抗原夹心elisa抗体检测试剂盒及其应用 |
CN114907484A (zh) * | 2022-04-20 | 2022-08-16 | 中国科学院微生物研究所 | 一种强效抗新冠突变株包括奥密克戎四种亚型的双特异人源抗体 |
WO2024022438A1 (zh) * | 2022-07-29 | 2024-02-01 | 盛禾(中国)生物制药有限公司 | 一种抗rbd抗体及其用途 |
WO2024102674A1 (en) * | 2022-11-13 | 2024-05-16 | Generate Biomedicines, Inc. | Antigen binding molecules targeting sars-cov-2 |
CN116284363A (zh) * | 2023-05-15 | 2023-06-23 | 北京百普赛斯生物科技股份有限公司 | 新型冠状病毒OmicronBA.2/4/5突变株特异性抗体及其应用 |
CN116284363B (zh) * | 2023-05-15 | 2023-09-29 | 北京百普赛斯生物科技股份有限公司 | 新型冠状病毒OmicronBA.2/4/5突变株特异性抗体及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN114292327B (zh) | 2022-07-12 |
WO2023168776A1 (zh) | 2023-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114292327B (zh) | 一种广谱新型冠状病毒的人源抗体及其应用 | |
CN111995675B (zh) | 一种针对新冠病毒SARS-CoV-2棘突蛋白RBD区的单克隆抗体及其应用 | |
CN113444170B (zh) | 针对新冠病毒SARS-CoV-2的单克隆抗体F10 | |
JP7289562B2 (ja) | 抗bcma単一ドメイン抗体及びその適用 | |
CN110317267B (zh) | 针对狂犬病病毒的双特异性抗体及其用途 | |
CN113861288B (zh) | 新型冠状病毒SARS-CoV-2广谱中和抗体及其应用 | |
CN111057145B (zh) | 猪繁殖与呼吸综合征病毒Nsp2蛋白纳米抗体及其应用 | |
Rani et al. | Increased antibody affinity confers broad in vitro protection against escape mutants of severe acute respiratory syndrome coronavirus | |
CN110684102B (zh) | 一种sftsv检测试剂盒 | |
CN114384245B (zh) | 新型冠状病毒s-rbd蛋白和n蛋白双表位识别的联检试剂盒及其应用 | |
CN108892723B (zh) | 用于检测猪流行性腹泻病毒的单域重链抗体、制备方法及应用 | |
CN106188283B (zh) | 甲型禽流感h7n2的纳米抗体及其应用 | |
CN114397452B (zh) | 新型冠状病毒Delta突变株或原型株检测试剂盒及其应用 | |
CN114456264B (zh) | 一种新型冠状病毒稀有广谱表位的人源抗体及其应用 | |
CN114395034B (zh) | 一种高效中和新型冠状病毒的人源抗体及其应用 | |
Cao et al. | Discovery and development of human SARS-CoV-2 neutralizing antibodies using an unbiased phage display library approach | |
Madan et al. | Antibody screening at reduced pH enables preferential selection of potently neutralizing antibodies targeting SARS‐CoV‐2 | |
Zheng et al. | Vaccine Molecule Design Based on Phage Display and Computational Modeling against Rhabdovirus | |
CN117164705B (zh) | 一种靶向h5亚型禽流感病毒血凝素蛋白的纳米抗体 | |
CN117487006B (zh) | 一种抗a型塞内卡病毒的单克隆抗体以及抗原表位及应用 | |
Zhao et al. | Isolation and identification of an scFv antibody against nucleocapsid protein of SARS-CoV | |
Moldovan Loomis et al. | AI-based antibody discovery platform identifies novel, diverse and pharmacologically active therapeutic antibodies against multiple SARS-CoV-2 strains | |
CN117285603A (zh) | 基于连接肽的双特异纳米抗体及其编码基因和应用 | |
CN117069830A (zh) | 一种针对新型冠状病毒的纳米抗体及其应用 | |
Rong-Hong et al. | Identification of a mimotope peptide bound to the SARS-CoV spike protein specific monoclonal antibody 2C5 with phage-displayed peptide library |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Gao Fu Inventor after: Tong Zhou Inventor after: Tong Jianyu Inventor after: Cui Qingwei Inventor after: Zhao Xin Inventor after: Wang Qihui Inventor before: Gao Fu Inventor before: Tong Zhou Inventor before: Liu Kefang Inventor before: Zhao Xin Inventor before: Wang Qihui Inventor before: Wang Likui Inventor before: Xie Yi Inventor before: Ma Sufang |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220620 Address after: 100101 courtyard 1, Beichen West Road, Chaoyang District, Beijing Applicant after: INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCES Applicant after: Shanxi Institute of higher innovation Address before: 100101 No. 1 West Beichen Road, Beijing, Chaoyang District Applicant before: INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCES |
|
GR01 | Patent grant | ||
GR01 | Patent grant |